Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo

Blood

Volumn 103, Issue 4, 2004, Pages 1356-1363

  Schick, Barbara P ^a   Maslow, David ^a   Moshinski, Adrianna ^a   San Antonio, James D ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLARGINYLLYSYLLYSYLALANYLALANYLLYSYLALANYLALANYLARGINYLLYSYLLYSYLALANYL ALANYLLYSYLALANYLALANYLARGINYLLYSYLLYSYLALANYLALANYLLYSYLALANYLVALYLLEUCYLVALYLL EUCYLVALYLLEUCYLVALYLLEUCINE; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN BINDING PROTEIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLEEDING; BLOOD CLOTTING; BLOOD PRESSURE MEASUREMENT; CONSENSUS SEQUENCE; CONTROLLED STUDY; CYCLIZATION; DISSOCIATION CONSTANT; DRUG POTENCY; DRUG PROTEIN BINDING; HEART RATE; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; MALE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; RAT; TANDEM REPEAT; THROMBOSIS;

EID: 0842264034     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2334     Document Type: Article

References (22)

1. Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis. 1986;16:139-146.
2. Doutremepuich C, Bonini F, Toulemonde F, Bertrand H, Bayrou B, Quilichini R. In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine. Semin Thromb Hemost. 1985;11:318-322.
3. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arterioscler. 1989;9:21-32.
4. Schick BP, Gradowski JF, San Antonio JD, Martinez J. Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans. Thromb Haemost. 2001;85:482-487.
5. Verrecchio A, Germann MW, Schick BP, Kung B, Twardowski T, San Antonio JD. Design of peptides with high affinities for heparin and endothelial cell proteoglycans. J Biol Chem. 2000;275:7701-7707.
6. Lee MK, Lander AD. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. Proc Natl Acad Sci U S A. 1991;88:2768-2772.
7. Lindblad B, Borgstrom A, Wakefield TW, Whitehouse WM Jr, Stanley JC. Protamine reversal of anticoagulation achieved with a low molecular weight heparin: the effects on eicosanoids, clotting and complement factors. Thromb Res. 1987;48:31-40.
8. Gram J, Mercker S, Bruhn HD. Does protamine chloride neutralize low molecular weight heparin sufficiently? Thromb Res. 1988;52:353-359.
9. Guo X, Han IS, Yang VC, Meyerhoff ME. Homogeneous enzyme-based binding assay for studying glycosaminoglycan interactions with macromolecules and peptides. Anal Biochem. 1996;235:153-160.
10. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S-94S.
11. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety [erratum appears in Chest. 1999;115:1760]. Chest. 1998;114:489S-510S.
12. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety [erratum appears in Chest. 1999;115:1760]. Chest. 1998;114:489S-510S.
13. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Brit J Haematol. 2002;116:178-186.
14. Wakefield TW, Andrews PC, Wrobleski SK, et al. A [+18RGD]protamine variant for nontoxic and effective reversal of conventional heparin and low molecular weight heparin anticoagulation. J Surg Res. 1996;63:280-286.
15. Shenoy S, Sobel M, Harris RB. Development of heparin antagonists with focused biological activity. Curr Pharm Design. 1999;5:965-986.
16. Chang LC, Liang JF, Lee HF, Lee LM, Yang VC. Low molecular weight protamine (LMWP) as non-toxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity. AAPS PharmSci. 2001;3:E18.
17. Chang LC, Lee HF, Yang Z, Yang VC. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization. AAPS PharmSci. 2001;3:E17.
18. Lee LM, Chang LC, Wrobleski S, Wakefield TW, Yang VC. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci. 2001;3:E19.
19. Hulin MS, Wakefield TW, Andrews PC, et al. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model. Lab Anim Sci. 1997;47:153-160.
20. Lundequist A, Juliano MA, Juliano L, Pejler G. Polycationic peptides as inhibitors of mast cell serine proteases. Biochem Pharmacol. 2003;65:1171-1180.
21. Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001;58(suppl 2):S14-S17.
22. Sundaram M, Qi Y, Shriver Z, at al. Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci U S A. 2003;100:651-656.